Apogossypol Derivatives As Antagonists of Antiapoptotic Bcl-2 Family Proteins.
Jun Wei,Shinichi Kitada,Michele F. Rega,Aras Emdadi,Hongbin Yuan,Jason Cellitti,John L. Stebbins,Dayong Zhai,Jiazhi Sun,Li Yang,Russell Dahl,Ziming Zhang,Bainan Wu,Si Wang,Tyler A. Reed,Nicholas Lawrence,Said Sebti,John C. Reed,Maurizio Pellecchia
DOI: https://doi.org/10.1158/1535-7163.mct-08-1050
2009-01-01
Molecular Cancer Therapeutics
Abstract:Abstract Guided by a combination of nuclear magnetic resonance binding assays and computational docking studies, we synthesized a library of 5,5′ substituted Apogossypol derivatives as potent Bcl-XL antagonists. Each compound was subsequently tested for its ability to inhibit Bcl-XL in an in vitro fluorescence polarization competition assay and exert single-agent proapoptotic activity in human cancer cell lines. The most potent compound BI79D10 binds to Bcl-XL, Bcl-2, and Mcl-1 with IC50 values of 190, 360, and 520 nmol/L, respectively, and potently inhibits cell growth in the H460 human lung cancer cell line with an EC50 value of 680 nmol/L, expressing high levels of Bcl-2. BI79D10 also effectively induces apoptosis of the RS11846 human lymphoma cell line in a dose-dependent manner and shows little cytotoxicity against bax−/−bak−/− mouse embryonic fibroblast cells, in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that BI79D10 has little off-target effects. BI79D10 displays in vivo efficacy in transgenic mice, in which Bcl-2 is overexpressed in splenic B cells. Together with its improved plasma and microsomal stability relative to Apogossypol, BI79D10 represents a lead compound for the development of novel apoptosis-based therapies for cancer. [Mol Cancer Ther 2009;8(4):904–13]